Active Filter(s):
Details:
The agreement aims to combine company's expertise in the research of new phages and phage-derived proteins (endolysins) in the fight against antimicrobial resistance.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: PHAXIAM Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 03, 2023